Neurocrine Biosciences

This Phase 3 study tests whether adding NBI-1065845 to standard antidepressants can delay the return of depressive symptoms in adults with major depression. About 550 people who have not fully responded to current antidepressants will take either the study drug or a placebo pill.…

This study tests a new drug called NBI-1117570 in 120 adults with schizophrenia who need hospital care. The goal is to see if it improves symptoms like hallucinations and disorganized thinking better than a placebo. Participants take the drug or a placebo daily for 35 days, and r…

This study tests whether valbenazine can reduce involuntary muscle movements (tardive dyskinesia) in adults who still have symptoms while taking or after stopping another similar drug. About 50 people with schizophrenia, bipolar disorder, or major depression will take valbenazine…

This Phase 3 trial tests whether the experimental drug NBI-1117568 can delay relapse of schizophrenia symptoms compared to a placebo. About 560 adults with stable schizophrenia will first receive the drug openly, then be randomly assigned to continue it or switch to placebo. The …

This phase 3 trial is testing the long-term safety of the drug NBI-1117568 in 600 adults with schizophrenia. Participants will receive the drug and be monitored for side effects over time. The study is open-label, meaning everyone knows they are getting the drug, and it focuses o…

This Phase 3 trial tests whether a new drug called NBI-1117568 can improve schizophrenia symptoms like hallucinations and disorganized thinking. About 284 adults with schizophrenia who need hospital care will receive either the drug or a placebo for 5 weeks. The study measures sy…

This Phase 3 study is testing the long-term safety of an experimental drug called NBI-1065845 (TAK-653) in 850 adults with major depressive disorder who haven't gotten enough relief from standard antidepressants. Participants take the drug alongside their usual antidepressant for…

This study tests an experimental drug, NBI-1065890, to see if it can reduce involuntary movements in adults with tardive dyskinesia, a condition often caused by long-term use of certain mental health medications. About 100 participants with schizophrenia, bipolar disorder, or dep…

This Phase 3 trial is testing whether an experimental drug called NBI-1065845 can help reduce depression symptoms in adults who haven't responded well to standard antidepressants. About 200 participants will take either the drug or a placebo alongside their current antidepressant…

This study tests an experimental drug called NBI-1117568 for adults with bipolar I disorder who are hospitalized for a manic episode. Half of the 150 participants will get the drug, half a placebo, to see if it safely reduces manic symptoms over 21 days. The goal is to find a new…

This study tests an experimental drug, NBI-1117568, to see if it improves schizophrenia symptoms like hallucinations and delusions better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a placebo for 5 weeks. The main goal is to me…

This Phase 3 trial tests whether adding NBI-1065845 to standard antidepressants can better ease depression symptoms in 200 adults who haven't fully responded to current treatments. Participants take the drug or a placebo for 8 weeks, and doctors measure changes in mood and daily …

This study tests whether adding NBI-1065845 to standard antidepressants can better relieve depression symptoms in adults who haven't gotten enough help from their current medication. About 200 participants will receive either the study drug or a placebo for 8 weeks. The main goal…